Combined Treatment of Vildagliptin/Metformin (Equmet) and Imeglimin (Twymeeg) with Clinical Efficacy-Reference-Cited by-同舟云学术

Combined Treatment of Vildagliptin/Metformin (Equmet) and Imeglimin (Twymeeg) with Clinical Efficacy

Published:2023-04-14 Issue:2 Volume:6 Page:69-75
ISSN:2582-0370
Container-title:Asploro Journal of Biomedical and Clinical Case Reports
language:en
Short-container-title:Asp Biomed Clin Case Rep

Author:

BANDO Hiroshi¹^ORCID,YAMASHITA Hisako²,KATO Yoshinobu²,OGURA Katsunori²,KATO Yoshikane²

Affiliation:

1. Tokushima University/Medical research, Tokushima, Japan; Kanaiso Hospital, Komatsushima, Tokushima, Japan

2. Kanaiso Hospital, Komatsushima, Tokushima, Japan

Abstract

Background: Vildagliptin/Metformin (EquMet) and imeglimin (Twymeeg) are effective oral hypoglycemic agents (OHAs) for patients with type 2 diabetes (T2D). Case Presentation: The patient was a 68-year-old male with T2D and fatty liver for several years. In November 2022, his HbA1c had increased to 8.2%, and he was started on Twymeeg, followed by EquMet. Results: Over the course of four months, the patient’s HbA1c value successfully decreased from 8.2% to 6.7%, and he did not experience any gastrointestinal adverse effects (GIAEs). Discussion and Conclusion: The combined treatment of EquMet and Twymeeg demonstrated clinical efficacy without any adverse effects. The Trials of IMeglimin for Efficacy and Safety (TIMES) provided various evidence of imeglimin’s effectiveness.

Publisher

Asploro Open Access Publications

Subject

General Medicine

Reference29 articles.

1. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes-2023. Diabetes Care. 2023 Jan 1;46(Supple 1):S10-18. [PMID: 36507639]

2. Schillinger D, Bullock A, Powell C, Fukagawa NK, Greenlee MC, Towne J, Gonzalvo JD, Lopata AM, Cook JW, Herman WH. The National Clinical Care Commission Report to Congress: Leveraging Federal Policies and Programs for Population-Level Diabetes Prevention and Control: Recommendations From the National Clinical Care Commission. Diabetes Care. 2023 Feb 1;46(2):e24-38. [PMID: 36701595]

3. Saleem SM, Bhattacharya S, Deshpande N. Non-communicable diseases, type 2 diabetes, and influence of front of package nutrition labels on consumer’s behaviour: Reformulations and future scope. Diabetes Metab Syndr. 2022 Feb;16(2):102422. [PMID: 35150963]

4. Wharton S, Calanna S, Davies M, Dicker D, Goldman B, Lingvay I, Mosenzon O, Rubino DM, Thomsen M, Wadden TA, Pedersen SD. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022 Jan;24(1):94-105. [PMID: 34514682]

5. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. Diabetes Care. 2023 Jan 1;46(Suppl 1):S140-57. [PMID: 36507650]

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Latest Pharmaceutical Development of Imeglimin Electrospinning Nanofibers for Diabetic Treatment;Diabetes Research: Open Access;2024-05-18

2. Actual Meal of Low Carbohydrate Diet (LCD) for Diabetic Patient Treated by Effective Imeglimin (Twymeeg);Asploro Journal of Biomedical and Clinical Case Reports;2023-07-31

3. Relieved Depressive State and Glycemic Control in Type 2 Diabetes (T2D) Patient Treated by Imeglimin (Twymeeg);Asploro Journal of Biomedical and Clinical Case Reports;2023-06-12

4. CT Image of Consolidation and Ground-Glass Opacification (GGO) of COVID-19 in Diabetic Patient;Asploro Journal of Biomedical and Clinical Case Reports;2023-05-20